{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:21:05Z","timestamp":1779294065000,"version":"3.51.4"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) has become one of the most prevalent chronic liver diseases worldwide, bringing risk of multiorgan disfunctions including cardiovascular events, complications of cirrhosis, and even malignance. In terms of health burden management, screening patients with high risk of MAFLD and providing individual comprehensive treatment is critical. Although there are numerous agents entering clinical trials for MAFLD treatment every year, there is still no effective approved drug. The nomenclature of MAFLD highlighted the concomitant metabolic disorders and obesity. MAFLD patients with type 2 diabetes had higher risk of developing liver cirrhosis and cancer, and would benefit from anti-hyperglycemic agents; overweight and obese patients may benefit more from weight loss therapies; for patients with metabolic syndrome, individual comprehensive management is needed to reduce the risk of adverse outcomes. In this review, we introduced the current status and advances of the treatment of MAFLD based on weight loss, improving insulin resistance, and management of cardiometabolic disorders, in order to provide individualized therapy approaches for patients with MAFLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000002091","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T14:01:26Z","timestamp":1646229686000},"page":"1009-1018","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic developments in metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1097","volume":"135","author":[{"given":"Yiwen","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jlao Tong University School of Medicine, Shanghai 200092, China"},{"name":"Shanghal Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangao","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jlao Tong University School of Medicine, Shanghai 200092, China"},{"name":"Shanghal Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12072-020-10038-w","article-title":"Extrahepatic manifestations and healthcare expenditures of nonalcoholic fatty liver disease in the Medicare population","volume":"14","author":"Sayiner","year":"2020","journal-title":"Hepatol Int"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/MCG.0000000000001270","article-title":"The prevalence of lean\/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"54","author":"Shi","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"R8-20250603","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","author":"Lim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/17474124.2021.1860019","article-title":"A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD","volume":"15","author":"Yilmaz","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/nu13010015","article-title":"Calorie-restricted Mediterranean and low-fat diets affect fatty acid status in individuals with nonalcoholic fatty liver disease","volume":"13","author":"Ristic-Medic","year":"2020","journal-title":"Nutrients"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/nu13051442","article-title":"Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"Vancells Lujan","year":"2021","journal-title":"Nutrients"},{"key":"R14-20250603","first-page":"6649142","article-title":"Metabolic and hepatic effects of energy-reduced anti-inflammatory diet in younger adults with obesity","volume":"2021","author":"Kendel Jovanovic","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management ofnon-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1097\/MEG.0000000000002110","article-title":"Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol\/saturated fatty acids","volume":"33","author":"Guveli","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1073\/pnas.1922344117","article-title":"Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease","volume":"117","author":"Luukkonen","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/dme.13826","article-title":"James Lind Alliance research priorities: what role do carbohydrates, fats and proteins have in the management of Type 2 diabetes, and are there risks and benefits associated with particular approaches?","volume":"36","author":"Dyson","year":"2019","journal-title":"Diabet Med"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/liv.14638","article-title":"Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4314\/ahs.v14i3.8","article-title":"Markers of liver function and inflammatory cytokines modulation by aerobic versus resisted exercise training for nonalcoholic steatohepatitis patients","volume":"14","author":"Abd El-Kader","year":"2014","journal-title":"Afr Health Sci"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41395-018-0283-5","article-title":"Smoking and the risk of non-alcoholic fatty liver disease: a cohort study","volume":"114","author":"Jung","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/1751-2980.12685","article-title":"Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)","volume":"20","author":"Fan","year":"2019","journal-title":"J Dig Dis"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"R31-20250603","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819879047","article-title":"Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction","volume":"12","author":"Ye","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"Bajaj","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.28958","article-title":"Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis","volume":"65","author":"Klebanoff","year":"2017","journal-title":"Hepatology"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"e190047","DOI":"10.1001\/jamanetworkopen.2019.0047","article-title":"Cost-effectiveness analysis of bariatric surgery for patients with nonalcoholic steatohepatitis cirrhosis","volume":"2","author":"Klebanoff","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","article-title":"A systematic review of bariatric surgery in patients with liver cirrhosis","volume":"25","author":"Jan","year":"2015","journal-title":"Obes Surg"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.14309\/ajg.0000000000000911","article-title":"Improving outcomes of bariatric surgery in patients with cirrhosis in the United States: a nationwide assessment","volume":"115","author":"Are","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11695-018-3562-8","article-title":"Outcomes of bariatric surgery in patients with cirrhosis","volume":"29","author":"Mi\u00f1ambres","year":"2019","journal-title":"Obes Surg"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/ajg.2010.363","article-title":"Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series","volume":"105","author":"Kenny","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3\u200ayears","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"R49-20250603","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD Study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0\u200amg vs once-daily liraglutide 1.2\u200amg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"25 384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","article-title":"Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol Res"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.dld.2020.08.021","article-title":"Antidiabetic drugs and non-alcoholic fatty liver disease: a systematic review, meta-analysis and evidence map","volume":"53","author":"Kumar","year":"2021","journal-title":"Dig Liver Dis"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepa-titis in patients with Type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10238-016-0438-x","article-title":"Senescence in hepatic stellate cells asa mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings","volume":"17","author":"Panebianco","year":"2017","journal-title":"Clin Exp Med"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidine-diones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2174\/1381612827666210315144821","article-title":"The effect of metformin on aminotransferase levels, metabolic parameters and body mass index in nonalcoholic fatty liver disease patients: a metaanalysis","volume":"27","author":"Hu","year":"2021","journal-title":"Curr Pharm Des"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"104799","DOI":"10.1016\/j.phrs.2020.104799","article-title":"The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with nonalcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: an up-to date systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharmacol Res"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pharep.2018.10.013","article-title":"Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease","volume":"71","author":"Handzlik","year":"2019","journal-title":"Pharmacol Rep"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3390\/ijms19102863","article-title":"Metformin: an old drug with new applications","volume":"19","author":"Zhou","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"E987","DOI":"10.1152\/ajpendo.00133.2013","article-title":"Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl\/6 mice","volume":"305","author":"Tajima","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40618-020-01392-5","article-title":"Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD\/NASH in individuals with and without obesity and metabolic disease","volume":"44","author":"Barchetta","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-019-0266-7","article-title":"Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs","volume":"15","author":"Ahmad","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.3390\/ijms22158298","article-title":"PPARs as metabolic sensors and therapeutic targets in liver diseases","volume":"22","author":"Monroy-Ramirez","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohe-patitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of nonalcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"R92-20250603","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","author":"Rinella","year":"2021","journal-title":"J Hepatol"},{"key":"R93-20250603","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","author":"Ratziu","year":"2021","journal-title":"J Hepatol"},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages\u2606","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41440-018-0040-6","article-title":"The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review","volume":"41","author":"Bor\u00e9m","year":"2018","journal-title":"Hypertens Res"},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41401-021-00822-1","article-title":"Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis","volume":"43","author":"Shi","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:07:08Z","timestamp":1748977628000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000002091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":106,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000002091","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}